luckydude777
9 months ago
VERY GOOD news! Company is NOT cash strapped!
"The First Convertible Debenture has been fully repaid, and as of January 4, 2024, the Companyβs obligation to issue and sell, and Yorkvilleβs obligation to purchase, the Second Convertible Debenture has been terminated. At the time of termination, there were no outstanding borrowings, advance notices or shares of Common Stock to be issued under the Securities Purchase Agreement. In addition, there were no fees due by the Company or Yorkville in connection with the termination of the Securities Purchase Agreement.
Whalatane
10 months ago
CHICAGO, January 02, 2024--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced that the American Medical Association (AMA) has assigned a dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analysis (PLA), 0440U, for the companyβs AI-driven coronary heart disease (CHD) detection test, PrecisionCHD. Receipt of this new CPT PLA code, which will be effective on April 1, 2024, is a significant step toward payer billing and payment, facilitating broader adoption of the first and only integrated genetic-epigenetic diagnostic blood test for CHD.
Congrats on the move.
Doubt if payers or patients will pay the $350 ? the Co wants for this test ...but so far the mkt's buying the hype
No position
Good luck
Kiwi